To evaluate the efficacy, safety and tolerability of pelacarsen administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis (CAVS)
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
